Comparative Pharmacology
Head-to-head clinical analysis: XACDURO COPACKAGED versus ZERBAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XACDURO COPACKAGED versus ZERBAXA.
XACDURO (COPACKAGED) vs ZERBAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulbactam-durlobactam: Sulbactam is a beta-lactamase inhibitor and also binds to penicillin-binding proteins (PBPs) of Acinetobacter baumannii, inhibiting cell wall synthesis. Durlobactam is a beta-lactamase inhibitor that protects sulbactam from degradation by certain beta-lactamases, including class A, C, and D serine beta-lactamases.
Zerbaxa is a combination of ceftolozane, a cephalosporin antibiotic, and tazobactam, a beta-lactamase inhibitor. Ceftolozane inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, leading to cell death. Tazobactam protects ceftolozane from degradation by certain beta-lactamases.
XACDURO (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) intravenously over 2 hours every 8 hours.
1.5 g (ceftolozane 1 g + tazobactam 0.5 g) intravenously every 8 hours infused over 1 hour.
None Documented
None Documented
Sulbactam: ~1 hour; durlobactam: ~2 hours. In patients with moderate to severe renal impairment, half-life may be prolonged up to 3-4 times, requiring dose adjustment.
Ceftolozane: ~3 hours; tazobactam: ~1 hour; prolonged in renal impairment.
Renal excretion of unchanged drug: sulbactam ~80%, durlobactam ~90% within 24 hours. Biliary/fecal elimination: minimal (<1%).
Primarily renal excretion: ceftolozane ~95% unchanged in urine, tazobactam ~80% unchanged in urine; biliary/fecal elimination <1%.
Category C
Category C
Cephalosporin/Beta-Lactamase Inhibitor Combination
Cephalosporin/Beta-Lactamase Inhibitor Combination